On January 18, 2022 Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ reported a peer-reviewed publication in the Journal of Medical Economics (View Source) citing the clinical and associated health economic benefits of lenzilumab (Press release, Humanigen, JAN 18, 2022, View Source [SID1234605654]). The publication demonstrated, in all cases, lenzilumab plus SOC improved all specified clinical outcomes compared with SOC alone. Lenzilumab plus SOC, resulted in an estimated cost savings of $13,190 per patient (net savings of $3,190, after an assumed price of $10,000 for lenzilumab) in those receiving remdesivir with baseline C-Reactive Protein (CRP) levels <150 mg/L, and aged <85 years, the primary analysis population in the fully enrolled ACTIV-5/BET-B study. In other subpopulations, per-patient savings were also observed, including those aged <85 years with baseline CRP <150mg/L with or without remdesivir (cost savings = $11,858, net cost savings = $1,858) and within the subpopulation of Black/African American patients with baseline CRP <150mg/L (cost savings = $23,154, net cost savings = $13,154).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This publication demonstrates the opportunity to realise significant cost savings for healthcare systems, while also improving outcomes for patients," said Dr. Adrian Kilcoyne, Chief Medical Officer, Humanigen. "With the current omicron surge, the importance of variant-agnostic and both clinically effective and cost-effective therapies is paramount."

This peer-reviewed publication highlights the significant costs of treating hospitalized COVID-19 patients and the economic benefits of potentially improving survival without ventilation, ventilator use, time to recovery, mortality, time in the ICU, and time to invasive mechanical ventilation, which may be associated with adding lenzilumab to standard of care from the US hospital perspective.

"During these unprecedented and challenging times, we are preparing to commercialize lenzilumab as a single day treatment which is variant-agnostic and, if authorized, a driver of clinical and economic value to patients and healthcare systems," said Edward P. Jordan, Chief Commercial Officer, Humanigen.